Enfortumab Vedotin

• Symbiotic-GU-06-A Study to Learn About the Study Medicine PF-08634404 Alone or In Combination With Enfortumab Vedotin in Adult Participants … Pending
  2025-523523-21-00 Phase I/II 2 countries Pfizer Inc.
• DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting
  2025-521644-37-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patient… Recruiting
  2024-515511-21-00 Phase II 1 country Grupo Espanol De Tumores Neuroendocrinos
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 Phase II 5 countries Gilead Sciences Inc.
• PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended
  2024-514163-26-00 Phase II 1 country Grupo Espanol Multidisciplinar De Melanoma
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended
  2023-507342-84-00 Phase III 9 countries Astrazeneca AB
• An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat… Ended
  2023-503421-19-00 Phase III 10 countries Seagen Inc.
• A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancer Ended
  2023-503391-24-00 Phase II 1 country Seagen Inc.
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelia… Ended
  2024-517571-20-00 Phase III 2 countries Astellas Pharma Global Development Inc.

Showing 1–9 of 9 trials